High drug prices have created barriers to accessing medications, and Gerard Anderson, PhD, of Johns Hopkins Bloomberg School of Public Health, suggests that the pricing algorithms need to change in order to improve this dilemma.
High drug prices have created barriers to accessing medications, and Gerard Anderson, PhD, of Johns Hopkins Bloomberg School of Public Health, suggests that the pricing algorithms need to change in order to improve this dilemma.
Transcript (slightly modified)
What do you view as the biggest barrier to access to medications?
I’m really focused on the high cost drugs. So, for that it’s really the price and we basically have a system where only about 20% of the people can afford these very expensive drugs because a program like Medicare puts very high cost-sharing on it. Medicaid doesn’t typically cover them, the Bureau of Prisons, the Indian Health Services, don’t cover those things because they’re so expensive. So, I think the major problem that I am seeing right now for many people is the very high cost drugs. For a lot of people, they just don’t have any money at all and so even having a very little cost sharing is devastating. A program like the Patient Access Network is critical for them but I think what new situation that is happening is that the very expensive drugs have become the problem.
How can access be improved?
Essentially for the very high cost drugs, we need to figure out a way to get price times quantity down, so that the price is way down and the quantity is way up. Right now, the pricing algorithms that most of the drug companies have assume that very few people will buy the drug at a very high price, and from a public health point of view, we want a lower price but a much higher quantity so that the drug companies still have the same revenue, but we essentially get as many people as possible covered.
In this interview with The American Journal of Managed Care®, Katie Queen, MD, addresses the complexity of obesity as a medical condition, pivoting to virtual care while ensuring that patients who lived in a rural location continued to receive adequate care, and the importance of integrating awareness of obesity and chronic disease prevention into local food culture.
Read More
Recent T1D Research Contradicts Common Assumptions About Patients
November 15th 2023Michael Fang, PhD, researcher and assistant professor in the division of Cardiovascular and Clinical Epidemiology at Johns Hopkins University, discussed recent findings in the type 1 diabetes (T1D) space that may alter the way providers address diabetes diagnoses.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen